Stratified risk of high-grade cervical disease using onclarity HPV extended genotyping in women, ≥25 years of age, with NILM cytology

被引:40
作者
Stoler, Mark H. [1 ]
Wright, Thomas C., Jr. [2 ]
Parvu, Valentin [3 ]
Yanson, Karen [3 ]
Cooper, Charles K. [3 ]
Andrews, Jeffrey [3 ]
机构
[1] Univ Virginia Hlth Syst, Charlottesville, VA 22908 USA
[2] Columbia Univ, New York, NY 10032 USA
[3] Becton Dickinson & Co, BD Life Sci, Diagnost Syst, 7 Loveton Circle, Sparks, MD 21152 USA
关键词
Cervical Cancer screening; Negative for intraepithelial lesions or malig-nancies; Human papillomavirus; Extended genotyping; Cervical intraepithelial neoplasia; Risk stratification; HUMAN-PAPILLOMAVIRUS GENOTYPE; INTRAEPITHELIAL NEOPLASIA; CANCER; MANAGEMENT; PREVENTION; GUIDELINES; PRECANCER; ATHENA; WORSE;
D O I
10.1016/j.ygyno.2018.12.024
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives. Increasing evidence suggests that extended human papillomavirus (HPV) genotyping (beyond 16/18) is effective for risk stratification in women with normal cytology. This report provides extended genotyping results, using the BD Onclarity HPV Assay, for individual genotypes HPV16, 18, 31, 45, 51, and 52- and three pooled genotype results for HPV33/58, 35/39/68, and 56/59/66. Methods. 27,037 women with normal cytology, >= 25 years, were enrolled into the Onclarity HPV trial during routine screening. Women positive for any HPV genotype were referred to colposcopy/biopsy. Hierarchical-ranked prevalence and risk values, associated with cervical intraepithelial neoplasia, grade 2 or worse (>= CIN2) or >= CIN3, were calculated based on extended genotyping results. Results. HPV 16 and 31 carried the highest risk for >= CIN2 (11.6% and 12.1%, respectively) and >= CIN3 (8.1% and 7.5%, respectively); these genotypes were the most prevalent in both >= CIN2 (29.6% and 19.3%, respectively) and >= CIN3 (43.7% and 22.5%, respectively). Of the other 12 genotypes, HPV 18, 33/58, and 52 comprised an intermediate risk band (>= CIN2 risk range: 4.9-6.8%; >= CIN3 risk range: 3.9-5.0%). Genotypes 45, 51, 35/39/68, and 56/59/ 66 constituted the lowest risk band for both disease grades (>= CIN2 value risk range: 1.7-3.0%; >= CIN3 value risk range: 12-3.6%). Conclusions. Extended genotyping stratifies risk for >= CIN2/3 in the >= 25 year-old, normal cytology population. While baseline HPV 16/31 values exceeded the risk threshold for colposcopy referral, the management of women with normal cytology who were positive for the intermediate- or lower-risk genotypes may evolve based on refined risk estimates as well as clinical factors. (C) 2019 The Authors. Published by Elsevier Inc.
引用
收藏
页码:26 / 33
页数:8
相关论文
共 31 条
[1]   Human papillomavirus type-specific 18-month risk of high-grade cervical intraepithelial neoplasia in women with a normal or borderline/mildly dyskaryotic smear [J].
Berkhof, Johannes ;
Bulkmans, Nicole W. J. ;
Bleeker, Maaike C. G. ;
Bulk, Saskia ;
Snijders, Peter J. F. ;
Voorhorst, Feja J. ;
Meijer, Chris J. L. M. .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2006, 15 (07) :1268-1273
[2]  
Bosch F Xavier, 2003, J Natl Cancer Inst Monogr, P3
[3]   High-risk HPV type-specific clearance rates in cervical screening [J].
Bulkmans, N. W. J. ;
Berkhof, J. ;
Bulk, S. ;
Bleeker, M. C. G. ;
van Kemenade, F. J. ;
Rozendaal, L. ;
Snijders, P. J. F. ;
Meijer, C. J. L. M. .
BRITISH JOURNAL OF CANCER, 2007, 96 (09) :1419-1424
[4]   Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study [J].
Castle, Philip E. ;
Stoler, Mark H. ;
Wright, Thomas C., Jr. ;
Sharma, Abha ;
Wright, Teresa L. ;
Behrens, Catherine M. .
LANCET ONCOLOGY, 2011, 12 (09) :880-890
[5]   The Lower Anogenital Squamous Terminology Standardization Project for HPV-associated Lesions: Background and Consensus Recommendations From the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology [J].
Darragh, Teresa M. ;
Colgan, Terence J. ;
Cox, J. Thomas ;
Heller, Debra S. ;
Henry, Michael R. ;
Luff, Ronald D. ;
McCalmont, Timothy ;
Nayar, Ritu ;
Palefsky, Joel M. ;
Stoler, Mark H. ;
Wilkinson, Edward J. ;
Zaino, Richard J. ;
Wilbur, David C. .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2013, 32 (01) :76-115
[6]   Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study [J].
de Sanjose, Silvia ;
Quint, Wim G. V. ;
Alemany, Laia ;
Geraets, Daan T. ;
Ellen Klaustermeier, Jo ;
Lloveras, Belen ;
Tous, Sara ;
Felix, Ana ;
Eduardo Bravo, Luis ;
Shin, Hai-Rim ;
Vallejos, Carlos S. ;
Alonso de Ruiz, Patricia ;
Lima, Marcus Aurelho ;
Guimera, Nuria ;
Clavero, Omar ;
Alejo, Maria ;
Llombart-Bosch, Antonio ;
Cheng-Yang, Chou ;
Alejandro Tatti, Silvio ;
Kasamatsu, Elena ;
Iljazovic, Ermina ;
Odida, Michael ;
Prado, Rodrigo ;
Seoud, Muhieddine ;
Grce, Magdalena ;
Usubutun, Alp ;
Jain, Asha ;
Hernandez Suarez, Gustavo Adolfo ;
Estuardo Lombardi, Luis ;
Banjo, Aekunbiola ;
Menendez, Clara ;
Javier Domingo, Efren ;
Velasco, Julio ;
Nessa, Ashrafun ;
Chichareon, Saibua C. Bunnag ;
Qiao, You Lin ;
Lerma, Enrique ;
Garland, Suzanne M. ;
Sasagawa, Toshiyuki ;
Ferrera, Annabelle ;
Hammouda, Doudja ;
Mariani, Luciano ;
Pelayo, Adela ;
Steiner, Ivo ;
Oliva, Esther ;
Meijer, Chris J. L. M. ;
Al-Jassar, Waleed Fahad ;
Cruz, Eugenia ;
Wright, Thomas C. ;
Puras, Ana .
LANCET ONCOLOGY, 2010, 11 (11) :1048-1056
[7]   Human papillomavirus types in 115,789 HPV-positive women: A meta-analysis from cervical infection to cancer [J].
Guan, Peng ;
Howell-Jones, Rebecca ;
Li, Ni ;
Bruni, Laia ;
de Sanjose, Silvia ;
Franceschi, Silvia ;
Clifford, Gary M. .
INTERNATIONAL JOURNAL OF CANCER, 2012, 131 (10) :2349-2359
[8]   Use of Primary High-Risk Human Papillomavirus Testing for Cervical Cancer Screening: Interim Clinical Guidance [J].
Huh, Warner K. ;
Ault, Kevin A. ;
Chelmow, David ;
Davey, Diane D. ;
Goulart, Robert A. ;
Garcia, Francisco A. ;
Kinney, Walter K. ;
Massad, L. Stewart ;
Mayeaux, Edward J. ;
Saslow, Debbie ;
Schiffman, Mark ;
Wentzensen, Nicolas ;
Lawson, Herschel W. ;
Einstein, Mark H. .
JOURNAL OF LOWER GENITAL TRACT DISEASE, 2015, 19 (02) :91-96
[9]   Benchmarking CIN 3+Risk as the Basis for Incorporating HPV and Pap Cotesting into Cervical Screening and Management Guidelines [J].
Katki, Hormuzd A. ;
Schiffman, Mark ;
Castle, Philip E. ;
Fetterman, Barbara ;
Poitras, Nancy E. ;
Lorey, Thomas ;
Cheung, Li C. ;
Raine-Bennett, Tina ;
Gage, Julia C. ;
Kinney, Walter K. .
JOURNAL OF LOWER GENITAL TRACT DISEASE, 2013, 17 :S28-S35
[10]   The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice [J].
Khan, MJ ;
Castle, PE ;
Lorincz, AT ;
Wacholder, S ;
Sherman, M ;
Scott, DR ;
Rush, BB ;
Glass, AG ;
Shiffman, M .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (14) :1072-1079